Skip to main content
OpenTrials
Completed

NCT Number: NCT03943160

Radial accEss for nAvigation to Your CHosen Lesion for Peripheral Vascular Intervention: REACH PVI

The objective of this study is to evaluate acute clinical results of orbital atherectomy (OA) via radial artery access, including complication rates and cost effectiveness.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Arizona Cardiovascular Research Center, Phoenix, Arizona, United States

Loading trial locations.

About this study

The purpose of this study is to prospectively evaluate acute clinical outcomes of orbital atherectomy (OA) via transradial access (TRA) for treatment of peripheral artery disease (PAD) in lower extremity lesions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is ≥ 18 years
  • Subject is willing and able to sign the IRB-approved informed consent form (ICF)
  • Subject presents with a Rutherford Classification of 2 to 5
  • Subject has a positive Allen's Test
  • Subject to undergo peripheral angiography and/or PVI via TRA approach per physician discretion

Index Procedure Inclusion Criteria:

  • Physician obtains successful radial artery access (Note: snuffbox access is allowed)
  • Target lesion appropriate (i.e. location/morphology) for OA treatment via TRA within target area
  • OAS use attempted (defined as ViperWire introduced into the body)

Exclusion criteria

  • Subject has no palpable radial artery on the planned access arm
  • Subject has a previous failed radial access attempt on planned access arm
  • Subject has a dialysis fistula on planned access arm
  • Subject has a known subclavian stenosis or occlusion
  • Subject has a previous subclavian stent or previous subclavian intervention
  • Subject has a shunt in the radial artery on the planned access arm
  • Subject has evidence of osteomyelitis
  • Subject is currently participating in an investigational drug or device study
  • Subject is pregnant within the study period

Index Procedure Exclusion Criteria

  • Physician unable to obtain radial artery access
  • Physician determines TRA is not acceptable due to patient anatomy, lesion characteristics, and/or disease severity
  • OAS use not attempted (defined as ViperWire introduced into the body)

Prior to insertion of ViperWire:

  • Femoral access is obtained
  • Unsuccessful peripheral intervention
  • A reportable adverse event has occurred

Treatment and study plan

Diamondback 360 Extended Length Orbital Atherectomy System

Device

All patients undergoing peripheral vascular intervention (PVI) via transradial access (TRA) and for whom TRA has been successfully achieved and peripheral lesion deemed appropriate for treatment via TRA per physician discretion.

Other names: Stealth 360 Extended Length Orbital Atherectomy System

Primary outcomes

  1. Procedural Success:

    Time frame: Participants were followed from the baseline procedure through the first site-specific standard of care follow-up visit (7-45 days post-procedure)

    Successful completion of OA (orbital atherectomy) treatment of target lesion via transradial access without serious transradial access (TRA) related events. Serious TRA related events consist of: Serious TRA site bleeding, serious TRA site hematoma, serious radial artery spasm, serious hand ischemia, stroke, Transient Ischemic Attach (TIA), Serious nerve damage, perforation, TRA site pseudoaneurysm.

Secondary outcomes

  1. Treatment Success:

    Time frame: Participants were followed from baseline procedure through hospital discharge, an expected average of less than 24 hours

    Treatment success is defined as <50% residual stenosis post-procedure and without significant angiographic complications without stent placement, or <30% residual stenosis post-procedure and without significant angiographic complications with stent placement.

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Registry information

Acronym: REACH PVI

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
May 9, 2019
Registry last updated
Jul 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.